REGENERON PHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Jul 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 30, 2026
REGN$916.06-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited)
(In millions, except per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Statements of Operations | ||||
| Revenues: | ||||
| Net product sales | $1,642.4 | $1,631.0 | $3,176.9 | $3,046.6 |
| Collaboration revenue | 2,455.0 | 1,860.7 | 4,354.7 | 3,391.9 |
| Other revenue | 193.3 | 183.9 | 364.5 | 265.8 |
| 4,290.7 | 3,675.6 | 7,896.1 | 6,704.3 | |
| Expenses: | ||||
| Research and development | 1,631.6 | 1,421.7 | 3,175.1 | 2,749.1 |
| Acquired in-process research and development | 127.0 | 10.0 | 228.9 | 22.3 |
| Selling, general, and administrative | 662.1 | 634.2 | 1,309.8 | 1,267.2 |
| Cost of goods sold | 360.7 | 275.6 | 734.1 | 541.1 |
| Cost of collaboration and contract manufacturing | 215.8 | 254.6 | 511.8 | 453.4 |
| 2,997.2 | 2,596.1 | 5,959.7 | 5,033.1 | |
| Income from operations | 1,293.5 | 1,079.5 | 1,936.4 | 1,671.2 |
| Other income (expense): | ||||
| Other income (expense), net | 245.3 | 442.8 | 446.5 | 764.8 |
| Interest expense | (11.0) | (3.6) | (23.9) | (12.3) |
| 234.3 | 439.2 | 422.6 | 752.5 | |
| Income before income taxes | 1,527.8 | 1,518.7 | 2,359.0 | 2,423.7 |
| Income tax expense | 230.9 | 127.1 | 334.9 | 223.4 |
| Net income | $1,296.9 | $1,391.6 | $2,024.1 | $2,200.3 |
| Net income per share - basic | $12.62 | $13.24 | $19.58 | $20.78 |
| Net income per share - diluted | $12.23 | $12.81 | $18.95 | $20.02 |
| Weighted average shares outstanding - basic | 102.8 | 105.1 | 103.4 | 105.9 |
| Weighted average shares outstanding - diluted | 106.0 | 108.6 | 106.8 | 109.9 |
| Statements of Comprehensive Income | ||||
| Net income | $1,296.9 | $1,391.6 | $2,024.1 | $2,200.3 |
| Other comprehensive income (loss), net of tax: | ||||
| Unrealized (loss) gain on debt securities | (48.0) | 22.1 | (113.8) | 60.2 |
| Gain on foreign currency translation | 0.3 | 1.3 | 0.5 | 0.2 |
| Comprehensive income | $1,249.2 | $1,415.0 | $1,910.8 | $2,260.7 |
| The accompanying notes are an integral part of the financial statements. | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.